Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Down 16.1% in April

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totalling 3,070,000 shares, a drop of 16.1% from the March 31st total of 3,660,000 shares. Based on an average trading volume of 400,200 shares, the short-interest ratio is presently 7.7 days. Approximately 8.9% of the company’s stock are sold short.

Analysts Set New Price Targets

YMAB has been the subject of several research reports. Morgan Stanley reduced their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday, March 5th. Bank of America cut shares of Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price target for the company. in a research note on Tuesday, April 22nd. Wedbush reissued an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd. HC Wainwright decreased their price target on Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, March 21st. Finally, Truist Financial dropped their price objective on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, March 5th. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Y-mAbs Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $17.40.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB stock opened at $4.41 on Friday. The business’s fifty day moving average is $4.70 and its 200-day moving average is $7.79. Y-mAbs Therapeutics has a 1 year low of $3.84 and a 1 year high of $17.47. The stock has a market cap of $199.67 million, a PE ratio of -8.17 and a beta of 0.53.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period in the prior year, the company earned ($0.02) earnings per share. Equities research analysts predict that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

Insider Activity

In related news, insider Thomas Gad sold 10,810 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the transaction, the insider now owns 202,721 shares of the company’s stock, valued at $1,060,230.83. This represents a 5.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 22.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in YMAB. KLP Kapitalforvaltning AS acquired a new stake in shares of Y-mAbs Therapeutics in the fourth quarter worth about $46,000. ProShare Advisors LLC bought a new stake in Y-mAbs Therapeutics during the fourth quarter worth approximately $99,000. Exchange Traded Concepts LLC raised its position in shares of Y-mAbs Therapeutics by 107.9% in the first quarter. Exchange Traded Concepts LLC now owns 26,762 shares of the company’s stock valued at $119,000 after purchasing an additional 13,890 shares during the period. Wells Fargo & Company MN lifted its stake in shares of Y-mAbs Therapeutics by 54.1% in the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock worth $137,000 after buying an additional 6,131 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in shares of Y-mAbs Therapeutics by 30.7% during the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock worth $139,000 after buying an additional 4,163 shares during the period. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.